Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Reinisch, Walter"" wg kryterium: Autor


Tytuł :
Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
Autorzy :
Narula N; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Wong ECL; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Aruljothy A; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Marshall JK; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Reinisch W; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło :
The American journal of gastroenterology [Am J Gastroenterol] 2020 Aug; Vol. 115 (8), pp. 1236-1245.
Typ publikacji :
Journal Article
MeSH Terms :
Crohn Disease*
Severity of Illness Index*
Ileum/*pathology
Rectum/*pathology
Adult ; Colonoscopy ; Female ; Humans ; Male ; Prognosis
Czasopismo naukowe
Tytuł :
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
Autorzy :
Panaccione R; Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Alberta, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine Vanasek, Division of Gastroenterology and Hepatology, New York, New York, USA.
Travis SPL; Gastroenterology, John Radcliffe Hospital, Oxford, UK.
Bossuyt P; Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Baert F; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Vaňásek T; Division of Gastroenterology and Hepatology, Hepato-Gastroenterologie HK, sro, Hradec Králové, Czech Republic.
Danalıoğlu A; Gastroenterology Department, Bezmialem Vakıf University, Istanbul, Turkey.
Novacek G; Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria.
Armuzzi A; Internal Medicine and Gastroenterology, Catholic University, Rome, Italy.
Reinisch W; Department of Medicine IV, Medical University Vienna, Vienna, Austria.
Johnson S; Medicus Economics LCC., Milton, Maine, USA.
Buessing M; Medicus Economics, Boston, Massachusetts, USA.
Neimark E; AbbVie Inc., North Chicago, Illinois, USA.
Petersson J; AbbVie Inc., North Chicago, Illinois, USA.
Lee WJ; AbbVie Inc., North Chicago, Illinois, USA.
D'Haens GR; Gastroenterology, AMC, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Gut [Gut] 2020 Apr; Vol. 69 (4), pp. 658-664. Date of Electronic Publication: 2019 Jul 08.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Crohn Disease/*drug therapy
Biomarkers/metabolism ; C-Reactive Protein/metabolism ; Cost-Benefit Analysis ; Crohn Disease/metabolism ; Hospitalization ; Humans ; Leukocyte L1 Antigen Complex/metabolism ; Quality-Adjusted Life Years ; Symptom Assessment ; Treatment Outcome ; United Kingdom
Czasopismo naukowe
Tytuł :
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
Autorzy :
Lewis JD; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rutgeerts P; Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Feagan BG; Department of Medicine, University of Western Ontario, London, Ontario, Canada.
D'haens G; Academic Medical Center, Amsterdam, the Netherlands.
Danese S; Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mt Sinai, New York, New York, USA.
Reinisch W; Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Rubin DT; University of Chicago Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
Selinger C; Leeds Gastroenterology Institute, St James University Hospital, Leeds, United Kingdom.
Bewtra M; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Barcomb L; AbbVie Inc., North Chicago, Illinois, USA.
Lacerda AP; AbbVie Inc., North Chicago, Illinois, USA.
Wallace K; AbbVie Inc., North Chicago, Illinois, USA.
Butler JW; AbbVie Inc., North Chicago, Illinois, USA.
Wu M; AbbVie Inc., North Chicago, Illinois, USA.
Zhou Q; AbbVie Inc., North Chicago, Illinois, USA.
Liao X; AbbVie Inc., North Chicago, Illinois, USA.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Jan 06; Vol. 26 (2), pp. 304-313.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Abdominal Pain/*diagnosis
Anti-Inflammatory Agents/*therapeutic use
Constipation/*diagnosis
Crohn Disease/*drug therapy
Diarrhea/*diagnosis
Endoscopy, Gastrointestinal/*methods
Abdominal Pain/chemically induced ; Adult ; Clinical Trials as Topic ; Constipation/chemically induced ; Crohn Disease/pathology ; Diarrhea/chemically induced ; Drug Monitoring ; Endpoint Determination/standards ; Female ; Follow-Up Studies ; Humans ; Intestinal Mucosa/drug effects ; Male ; Prognosis ; Research Design ; Wound Healing/drug effects
Czasopismo naukowe
Tytuł :
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Autorzy :
Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Reinisch W; Department of Internal Medicine III, Division Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria.
Panaccione R; Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Berg S; AbbVie AB, Solna, Sweden.
Alperovich G; AbbVie Spain S.L.U., Madrid, Spain.
Bereswill M; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Kalabic J; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Petersson J; AbbVie Inc., North Chicago, Illinois, USA.
Thakkar R; AbbVie Inc., North Chicago, Illinois, USA.
Robinson AM; AbbVie Inc., North Chicago, Illinois, USA.
D'Haens G; Academic Medical Center, Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Aug 20; Vol. 25 (9), pp. 1522-1531.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Crohn Disease/*drug therapy
Registries/*statistics & numerical data
Adult ; Crohn Disease/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Autorzy :
Colombel JF; Department of Gastroenterology, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York. Electronic address: .
Adedokun OJ; Janssen Research & Development, Spring House, Pennsylvania.
Gasink C; Janssen Scientific Affairs, Horsham, Pennsylvania.
Gao LL; Janssen Scientific Affairs, Horsham, Pennsylvania.
Cornillie FJ; MSD International, Kriens, Switzerland.
D'Haens GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Rutgeerts PJ; Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Reinisch W; Universitätsklinik für Innere Medizin III, Vienna, Austria.
Sandborn WJ; Division of Gastroenterology and Department of Medicine, University of California, San Diego, San Diego, California.
Hanauer SB; Department of Medicine, Digestive Health Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2019 Jul; Vol. 17 (8), pp. 1525-1532.e1. Date of Electronic Publication: 2018 Sep 26.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Azathioprine/*pharmacokinetics
Crohn Disease/*drug therapy
Infliximab/*pharmacokinetics
Remission Induction/*methods
Adult ; Crohn Disease/blood ; Drug Therapy, Combination ; Female ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review.
Autorzy :
Panes J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona 08036, Spain.
Reinisch W; Medical University of Vienna, Vienna 1090, Austria.
Rupniewska E; RTI Health Solutions, Manchester M20 2LS, United Kingdom.
Khan S; RTI Health Solutions, Research Triangle Park, NC 27709, United States. .
Forns J; RTI Health Solutions, Barcelona 08028, Spain.
Khalid JM; Takeda, Deerfield, IL 60015, United States.
Bojic D; Takeda, Deerfield, IL 60015, United States.
Patel H; Takeda, Deerfield, IL 60015, United States.
Pokaż więcej
Źródło :
World journal of gastroenterology [World J Gastroenterol] 2018 Nov 14; Vol. 24 (42), pp. 4821-4834.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Cost of Illness*
Quality of Life*
Crohn Disease/*complications
Cutaneous Fistula/*epidemiology
Rectal Fistula/*epidemiology
Adipose Tissue/cytology ; Combined Modality Therapy/methods ; Cutaneous Fistula/etiology ; Cutaneous Fistula/therapy ; Drainage/methods ; Humans ; Immunosuppressive Agents/therapeutic use ; Rectal Fistula/etiology ; Rectal Fistula/therapy ; Recurrence ; Stem Cell Transplantation ; Stem Cells ; Treatment Failure ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
Autorzy :
Sandborn WJ; Department of Medicine, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Lee SD; Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington, USA.
Tarabar D; Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia.
Louis E; Department of Gastroenterology, University Hospital CHU of Liege, Liège, Belgium.
Klopocka M; Department of Vascular Diseases and Internal Medicine, Nicolaus Copernicus University, Toruń, Collegium Medicum in Bydgoszcz, Poland.
Klaus J; Department of Medicine, Universitatsklinikum Ulm, Ulm, Germany.
Reinisch W; Department of Medicine, Division of Gastroenterology, Medical University of Vienna, Vienna, Austria.; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Canada.
Hébuterne X; Department of Medicine, Université de Nice Sophia Antipolis, Hôpital de l'Archet, Nice, France.
Park DI; Department of Internal Medicine, Division of Gastroenterology, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea.
Schreiber S; Department of Medicine, University of Kiel, Kiel, Germany.
Nayak S; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Ahmad A; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Banerjee A; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Brown LS; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Cataldi F; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Gorelick KJ; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Cheng JB; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Hassan-Zahraee M; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Clare R; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
D'Haens GR; IBD Unit, Academic Medical Center, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Gut [Gut] 2018 Oct; Vol. 67 (10), pp. 1824-1835. Date of Electronic Publication: 2017 Oct 05.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/adverse effects
Crohn Disease*/diagnosis
Crohn Disease*/drug therapy
Crohn Disease*/metabolism
Adult ; Aged ; C-Reactive Protein/analysis ; Colonoscopy/methods ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Monitoring/methods ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Humans ; Male ; Middle Aged ; Patient Acuity ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Ustekinumab - Current position].
Autorzy :
Siegmund B; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany.
Högenauer C; Klinische Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Österreich.
Novacek G; Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich/Austria.
Petritsch W; Klinische Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Österreich.
Reinisch W; Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich/Austria.
Schoepfer A; Centre hospitalier universitaire vaudois, Service de gastro-énterologie et d'hépatologie, Lausanne, Schweiz.
Schreiber S; Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel.
Vavricka S; Zentrum für Gastroenterologie und Hepatologie, Zürich, Schweiz.
Bokemeyer B; Gastroenterologische Gemeinschaftspraxis Minden.
Pokaż więcej
Transliterated Title :
Ustekinumab – eine Standortbestimmung.
Corporate Authors :
für die IBD-Dach-Gruppe
Źródło :
Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2018 Sep; Vol. 56 (9), pp. 1077-1086. Date of Electronic Publication: 2018 Aug 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Crohn Disease*/drug therapy
Ustekinumab*/adverse effects
Ustekinumab*/pharmacology
Ustekinumab*/therapeutic use
Humans ; Inflammatory Bowel Diseases/drug therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
Autorzy :
DʼHaens G; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Reinisch W; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Panaccione R; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Satsangi J; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Petersson J; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Bereswill M; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Arikan D; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Perotti E; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Robinson AM; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Kalabic J; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Alperovich G; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Thakkar R; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Loftus EV; Academic Medical Center, Amsterdam, Netherlands. Medical university of Vienna, Vienna, Austria. Department of Medicine, university of Calgary, Calgary, Canada. Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. AbbVie Inc., North Chicago, IL, USA. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. AbbVie Spain S.L.U., Madrid, Spain. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
Pokaż więcej
Źródło :
The American journal of gastroenterology [Am J Gastroenterol] 2018 Jun; Vol. 113 (6), pp. 872-882. Date of Electronic Publication: 2018 Jun 05.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Adalimumab/*adverse effects
Crohn Disease/*drug therapy
Immunosuppressive Agents/*adverse effects
Lymphoma/*epidemiology
Registries/*statistics & numerical data
Adult ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/immunology ; Crohn Disease/immunology ; Crohn Disease/mortality ; Female ; Follow-Up Studies ; Humans ; Infections/epidemiology ; Infections/immunology ; Injection Site Reaction/epidemiology ; Injection Site Reaction/immunology ; Lymphoma/immunology ; Male ; Middle Aged ; Prospective Studies ; Skin Diseases/epidemiology ; Skin Diseases/immunology ; Survival Rate
Czasopismo naukowe
Tytuł :
Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.
Autorzy :
Louis EJ; University Hospital CHU of Liège, Liège, Belgium. .
Reinisch W; McMaster University, Hamilton, ON, Canada.; Medical University of Vienna, Vienna, Austria.
Schwartz DA; Vanderbilt University, Nashville, TN, USA.
Löfberg R; Karolinska Institutet, Sophiahemmet, Stockholm, Sweden.
Robinson AM; AbbVie Inc., North Chicago, IL, USA.
Berg S; AbbVie Inc., North Chicago, IL, USA.
Wang AW; AbbVie Inc., North Chicago, IL, USA.
Maa JF; AbbVie Inc., North Chicago, IL, USA.
Huang B; AbbVie Inc., North Chicago, IL, USA.
Pappalardo B; AbbVie Inc., North Chicago, IL, USA.
Pokaż więcej
Źródło :
Advances in therapy [Adv Ther] 2018 Apr; Vol. 35 (4), pp. 563-576. Date of Electronic Publication: 2018 Mar 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adalimumab/*therapeutic use
Crohn Disease/*complications
Crohn Disease/*drug therapy
Arthritis/drug therapy ; Arthritis/etiology ; Chronic Disease ; Eye Diseases/drug therapy ; Eye Diseases/etiology ; Humans ; Skin Diseases/drug therapy ; Skin Diseases/etiology
Czasopismo naukowe
Tytuł :
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.
Autorzy :
Panés J; Department of Gastroenterology, Hospital Clínic, IDIBAPS, CIBERehd, Barcelona, Spain. Electronic address: .
García-Olmo D; Department of Surgery, Hospital U. Fundación Jiménez Díaz, Madrid, Spain.
Van Assche G; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria; McMaster University, Hamilton, Ontario, Canada.
Baumgart DC; Department of Gastroenterology and Hepatology, Charité Medical School - Humboldt-University of Berlin, Berlin, Germany.
Dignass A; Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.
Nachury M; Department of Gastroenterology and Hepatology, CHU Lille, Lille, France.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Kazemi-Shirazi L; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Grimaud JC; Department of Hepato-Gastroenterology, Hôpital Nord, Marseille, France.
de la Portilla F; Department of Surgery, Unit of Coloproctology, University Virgen del Rocio Hospital/IBiS/CSIC/University of Seville, Seville, Spain.
Goldin E; Digestive Diseases Institute, Sharee Zedek MC, Jerusalem, Israel.
Richard MP; TiGenix, Parque Tecnológico de Madrid, Madrid, Spain.
Diez MC; TiGenix, Parque Tecnológico de Madrid, Madrid, Spain.
Tagarro I; TiGenix, Parque Tecnológico de Madrid, Madrid, Spain.
Leselbaum A; TiGenix, Parque Tecnológico de Madrid, Madrid, Spain; CDD-Clinical Drug Development, S.L., Barcelona, Spain.
Danese S; Department of Gastroenterology, Istituto Clinico Humanitas IRCCS, Milano, Italy.
Pokaż więcej
Corporate Authors :
ADMIRE CD Study Group Collaborators
Źródło :
Gastroenterology [Gastroenterology] 2018 Apr; Vol. 154 (5), pp. 1334-1342.e4. Date of Electronic Publication: 2017 Dec 24.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Stem Cell Transplantation*/adverse effects
Adipose Tissue/*cytology
Crohn Disease/*complications
Rectal Fistula/*surgery
Adult ; Crohn Disease/diagnosis ; Double-Blind Method ; Europe ; Female ; Humans ; Intention to Treat Analysis ; Israel ; Magnetic Resonance Imaging ; Male ; Rectal Fistula/diagnostic imaging ; Rectal Fistula/etiology ; Remission Induction ; Risk Factors ; Time Factors ; Transplantation, Homologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Development of an index to define overall disease severity in IBD.
Autorzy :
Siegel CA; Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Whitman CB; Department of Health Services, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Spiegel BMR; Department of Health Services, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Feagan B; Robarts Clinical Trials, London, Ontario, Canada.
Sands B; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Loftus EV Jr; Mayo Clinic, Rochester, Minnesota, USA.
Panaccione R; University of Calgary, Calgary, Alberta, Canada.
D'Haens G; Academic Medical Center, Amsterdam, Netherlands.
Bernstein CN; University of Manitoba, Winnipeg, Manitoba, Canada.
Gearry R; University of Otago, Christchurch, New Zealand.
Ng SC; Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Mantzaris GJ; Evangelismos-PolyCliniki-Ophthalmiatreion Hospital, Athens, Greece.
Sartor B; University of North Carolina, Chapel Hill, North Carolina, USA.
Silverberg MS; Mount Sinai Hospital, Toronto, Ontario, Canada.
Riddell R; Mount Sinai Hospital, Toronto, Ontario, Canada.
Koutroubakis IE; University Hospital Heraklion, Crete, Greece.
O'Morain C; Faculty of Health Sciences Trinity College Dublin, Dublin, Ireland.
Lakatos PL; Semmelweis University, Budapest, Hungary.
McGovern DPB; Widjaja Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Reinisch W; McMaster University, Hamilton, Ontario, Canada.
Rogler G; University Hospital of Zuürich, Zurich, Switzerland.
Kruis W; University of Cologne, Koln, Germany.
Tysk C; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Schreiber S; University Hopital Schleswig Holstein, Kiel, Germany.
Danese S; Humanitas University, Milan, Italy.
Sandborn W; UCSD, San Diego, California, USA.
Griffiths A; Hospital for Sick Children, Toronto, Ontario, Canada.
Moum B; Oslo University Hospital and University Oslo, Oslo, Norway.
Gasche C; Medical University and General Hospital Vienna, Vienna, Austria.
Pallone F; University of Rome Tor Vergata, Rome, Italy.
Travis S; Oxford University Hospital, Oxford, UK.
Panes J; Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Hanauer S; Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
Peyrin-Biroulet L; Inserm U954 and CHU de Nancy, Lorraine University, Nancy, France.
Pokaż więcej
Źródło :
Gut [Gut] 2018 Feb; Vol. 67 (2), pp. 244-254. Date of Electronic Publication: 2016 Oct 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Colitis, Ulcerative/*complications
Crohn Disease/*complications
Intestinal Fistula/*etiology
Intestinal Mucosa/*pathology
Abdominal Abscess/etiology ; Activities of Daily Living ; Adult ; Aged ; Biological Products/therapeutic use ; C-Reactive Protein/metabolism ; Colitis, Ulcerative/blood ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/pathology ; Crohn Disease/pathology ; Crohn Disease/surgery ; Delphi Technique ; Female ; Humans ; Male ; Middle Aged ; Symptom Assessment
Czasopismo naukowe
Tytuł :
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
Autorzy :
D'Haens G; Academic Medical Center, Amsterdam, The Netherlands.
Vermeire S; Leuven University Hospital, Leuven, Belgium.
Vogelsang H; Medical University of Vienna, Vienna, Austria.
Allez M; Hôpital Saint-Louis, Université Paris Diderot, Paris, France.
Desreumaux P; University of Lille, Lille, France.
Van Gossum A; Erasme Hospital, Free University of Brussels, Brussels, Belgium.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Baumgart DC; Charité Medical School, Humboldt-University of Berlin, Berlin, Germany.
Ransohoff RM; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Comer GM; Kimberton Drug Development Consulting, Phoenixville, PA, USA.
Ahmad A; Pfizer, Cambridge, MA, USA.
Cataldi F; Pfizer, Cambridge, MA, USA.
Cheng J; Pfizer, Cambridge, MA, USA.
Clare R; Pfizer, Cambridge, MA, USA.
Gorelick KJ; Pfizer, Cambridge, MA, USA.
Kaminski A; Pfizer, Cambridge, MA, USA.
Pradhan V; Pfizer, Cambridge, MA, USA.
Rivers S; Pfizer, Cambridge, MA, USA.
Sikpi MO; Pfizer, Cambridge, MA, USA.
Zhang Y; Pfizer, Cambridge, MA, USA.
Hassan-Zahraee M; Pfizer, Cambridge, MA, USA.
Reinisch W; Medical University of Vienna, Vienna, Austria.; McMaster University, Hamilton, ON, Canada.
Stuve O; Neurology Section, VA North Texas Health Care System, Dallas, TX, USA.; Southwestern Medical Center, University of Texas, Dallas, TX, USA.; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2018 Jan 24; Vol. 12 (2), pp. 188-196.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Central Nervous System/*immunology
Crohn Disease/*immunology
Integrin beta Chains/*metabolism
T-Lymphocytes/*metabolism
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/pharmacology ; Crohn Disease/blood ; Crohn Disease/cerebrospinal fluid ; Female ; Humans ; Immunologic Surveillance/drug effects ; Immunosuppressive Agents/therapeutic use ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Lymphocyte Count ; Male ; Middle Aged ; T-Lymphocyte Subsets ; Young Adult
Czasopismo naukowe
Tytuł :
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Autorzy :
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: .
Panaccione R; Inflammatory Bowel Disease Unit, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Bossuyt P; Imelda General Hospital, Bonheiden, Belgium.
Lukas M; Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE Clinical Centre, Prague, Czech Republic; First Medical Faculty, Charles University, Prague, Czech Republic.
Baert F; AZ Delta, Roeselare-Menen, Belgium.
Vaňásek T; Hepato-Gastroenterologie HK, sro, Hradec Králové, Czech Republic.
Danalioglu A; Department of Gastroenterology, Bezmialem Vakif University, Istanbul, Turkey.
Novacek G; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Armuzzi A; Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy.
Hébuterne X; Service de Gastro-entérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France.
Travis S; Oxford University Hospitals, Oxford, UK.
Danese S; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Humanitas Clinical and Research Centre, Milan, Italy.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Sandborn WJ; Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Rutgeerts P; Department of Gastroenterology, University of Leuven, Leuven, Belgium.
Hommes D; Department of Medicine, University of California, Los Angeles, CA, USA.
Schreiber S; Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Neimark E; AbbVie Inc, North Chicago, IL, USA.
Huang B; AbbVie Inc, North Chicago, IL, USA.
Zhou Q; AbbVie Inc, North Chicago, IL, USA.
Mendez P; AbbVie Spain SLU, Madrid, Spain.
Petersson J; AbbVie Inc, North Chicago, IL, USA.
Wallace K; AbbVie Inc, North Chicago, IL, USA.
Robinson AM; AbbVie Inc, North Chicago, IL, USA.
Thakkar RB; AbbVie Inc, North Chicago, IL, USA.
D'Haens G; Academic Medical Center, Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2017 Dec 23; Vol. 390 (10114), pp. 2779-2789. Date of Electronic Publication: 2017 Oct 31.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Adalimumab/*therapeutic use
Antirheumatic Agents/*therapeutic use
Azathioprine/*therapeutic use
Crohn Disease/*drug therapy
Adolescent ; Adult ; Aged ; C-Reactive Protein/immunology ; Crohn Disease/immunology ; Disease Management ; Drug Therapy, Combination ; Female ; Glucocorticoids/therapeutic use ; Humans ; Male ; Middle Aged ; Prednisone/therapeutic use ; Remission Induction ; Severity of Illness Index ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy :
Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Aug 01; Vol. 11 (8), pp. 921-929.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/blood ; Dose-Response Relationship, Drug ; Double-Blind Method ; Feces/chemistry ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Male ; Middle Aged ; Remission Induction/methods ; Serum Albumin/analysis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Autorzy :
D'Haens G; Department of Gastroenterology, Academic MedicalCenter, Amsterdam, The Netherlands.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Medical University, Vienna, Austria and McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Ghosh S; Department of Gastroenterology, University of Calgary, Calgary, AB, Canada.
Prantera C; Department of Gastroenterology, A.O. San Camillo Forlanini, Rome, Italy.
Lindgren S; Department of Gastroenterology, Lund University, University Hospital Skane, Malmö, Sweden.
Hommes DW; Centre for Inflammatory Bowel Diseases, Univerisity of California Los Angeles, Los Angeles, CA, USA.
Huang Z; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Boice J; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Huyck S; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International GmbH, Lucerne, Switzerland.
Pokaż więcej
Corporate Authors :
ENCORE investigators
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jun 01; Vol. 11 (6), pp. 680-689.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Crohn Disease/*drug therapy
Gastrointestinal Agents/*adverse effects
Hematologic Diseases/*chemically induced
Infections/*chemically induced
Infliximab/*adverse effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents/adverse effects ; Azathioprine/adverse effects ; Demyelinating Diseases/chemically induced ; Drug Substitution ; Drug Therapy, Combination/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infusions, Intravenous/adverse effects ; Lymphoproliferative Disorders/chemically induced ; Male ; Mercaptopurine/adverse effects ; Mesalamine/adverse effects ; Methotrexate/adverse effects ; Middle Aged ; Mortality ; Narcotics/adverse effects ; Prednisone/adverse effects ; Prospective Studies ; Registries ; Risk Factors ; Sulfasalazine/adverse effects ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Autorzy :
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada; and Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Colombel JF; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
D'Haens G; Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands; and Imelda GI Clinical Research Center, Bonheiden, Belgium.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Rutgeerts P; Division of Gastroenterology, Department of Internal Medicine, University of Leuven, Leuven, Belgium.
Geboes K; Department of Pathology, University of Leuven, Leuven, Belgium.
Petersson J; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Eichner S; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Zhou Q; Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA.
Robinson AM; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Read HA; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Thakkar R; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Apr 01; Vol. 11 (4), pp. 425-434.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Adalimumab/*therapeutic use
Crohn Disease/*drug therapy
Adult ; Colonoscopy ; Crohn Disease/pathology ; Double-Blind Method ; Female ; Humans ; Intestinal Mucosa/pathology ; Male ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
Autorzy :
Panés J; Department of Gastroenterology, Hospital Clínic, IDIBAPS, Centro Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, Barcelona, Spain. Electronic address: .
García-Olmo D; Department of Surgery, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Van Assche G; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine, Division of Gastroenterology and Hepatology, McMaster University, Hamilton, ON, Canada.
Baumgart DC; Department of Gastroenterology and Hepatology, Charité Medical School-Humboldt-University of Berlin, Berlin, Germany.
Dignass A; Department of Medicine Klinik I, Agaplesion Markus Krankenhaus, Frankfurt, Germany.
Nachury M; Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Lille, Lille, France.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Kazemi-Shirazi L; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Grimaud JC; Department of Hepato-Gastroenterology, Hôpital Nord, Marseille, France.
de la Portilla F; Department of Surgery, Unit of Coloproctology, University Virgen del Rocio Hospital, Centro Superior de Investigaciones, University of Seville, Seville, Spain.
Goldin E; Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Richard MP; TiGenix, Parque Tecnológico de Madrid, Madrid, Spain.
Leselbaum A; TiGenix, Parque Tecnológico de Madrid, Madrid, Spain.
Danese S; Humanitas University, IBD Center, Department of Gastroenterology, Instituto Clinico Humanitas, Rozzano, Milan, Italy.
Pokaż więcej
Corporate Authors :
ADMIRE CD Study Group Collaborators
Źródło :
Lancet (London, England) [Lancet] 2016 Sep 24; Vol. 388 (10051), pp. 1281-90. Date of Electronic Publication: 2016 Jul 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adipose Tissue*
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells*
Crohn Disease/*complications
Rectal Fistula/*etiology
Rectal Fistula/*surgery
Adult ; Aged ; Combined Modality Therapy ; Double-Blind Method ; Europe ; Evidence-Based Medicine ; Female ; Humans ; Israel ; Male ; Middle Aged ; Rectal Fistula/pathology ; Rectal Fistula/therapy ; Transplantation, Homologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs.
Autorzy :
Gecse KB; First Department of Medicine, Semmelweis University, Budapest, Hungary .
Sebastian S; Inflammatory Bowel Disease Unit, Hull & East Yorkshire NHS Trust, Hull, UK.
Hertogh Gd; Department of Pathology, University of Leuven, Leuven, Belgium.
Yassin NA; Department of Colorectal Surgery, St Mark's Hospital and Academic Institute, London, UK.
Kotze PG; Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, PR, Brazil.
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Spinelli A; Colorectal Surgery Unit, Humanitas Research Hospital, Humanitas University, Milan, Italy.
Koutroubakis IE; Department of Gastroenterology, University Hospital Heraklion, Iraklio, Greece.
Katsanos KH; Division of Gastroenterology, Department of Medicine, School of Health Sciences, Ioannina, Greece.
Hart A; Inflammatory Bowel Disease Unit, St Mark's Hospital, London, UK.
van den Brink GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Rogler G; Division of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Bemelman WA; Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2016 Jul; Vol. 10 (7), pp. 758-65. Date of Electronic Publication: 2016 Jan 28.
Typ publikacji :
Consensus Development Conference; Journal Article; Systematic Review
MeSH Terms :
Crohn Disease/*physiopathology
Rectal Fistula/*etiology
Crohn Disease/therapy ; Humans ; Magnetic Resonance Imaging ; Outcome Assessment, Health Care/methods ; Rectal Fistula/diagnosis ; Rectal Fistula/pathology ; Rectal Fistula/therapy ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Autorzy :
Regueiro M; Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: .
Feagan BG; Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Zou B; Janssen Research & Development, LLC, Spring House, Pennsylvania.
Johanns J; Janssen Research & Development, LLC, Spring House, Pennsylvania.
Blank MA; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
Chevrier M; Janssen Research & Development, LLC, Spring House, Pennsylvania.
Plevy S; Janssen Research & Development, LLC, Spring House, Pennsylvania.
Popp J; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
Cornillie FJ; MSD International, Luzern, Switzerland.
Lukas M; Charles University, Prague, Czech Republic.
Danese S; Istituto Clinico Humanitas, Milan, Italy.
Gionchetti P; S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Hanauer SB; Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Reinisch W; McMaster University, Hamilton, Ontario, Canada; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Sandborn WJ; University of California San Diego, La Jolla, California.
Sorrentino D; Virginia Tech, Carilion School of Medicine, Roanoke, Virginia; Department of Clinical and Experimental Pathology, University of Udine School of Medicine, Udine, Italy.
Rutgeerts P; University Hospital Gasthuisberg, Leuven, Belgium.
Pokaż więcej
Corporate Authors :
PREVENT Study Group
Źródło :
Gastroenterology [Gastroenterology] 2016 Jun; Vol. 150 (7), pp. 1568-1578. Date of Electronic Publication: 2016 Mar 03.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Colectomy/*adverse effects
Crohn Disease/*drug therapy
Gastrointestinal Agents/*administration & dosage
Infliximab/*administration & dosage
Secondary Prevention/*methods
Adult ; Colon/pathology ; Colon/surgery ; Colonoscopy ; Crohn Disease/pathology ; Crohn Disease/surgery ; Double-Blind Method ; Female ; Humans ; Ileum/pathology ; Ileum/surgery ; Male ; Middle Aged ; Postoperative Period ; Recurrence ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies